Top Biotech companies in the world

Top Biotech companies in the world, explore the best biotech companies in the world with their advanced technology and futuristic approach.

Hundreds of companies in the biotechnology industry combine biology and technology to produce medicines and related products to treat diseases and medical conditions. The biotechnology industry today includes medical and testing companies as well as biofuels, biomaterials, emission controls and more.

Top Biotech companies in the world

Pharmaceutical firms such as Vertex Pharmaceuticals Inc. (VRTX) and Gilead Sciences Inc. (GILD) are some of the largest businesses in the industry. The clinical compound called remdesivir in Gilead is known to have the ability to treat COVID-19.

In general, these companies concentrate on the production and testing of new pharmaceutical drugs and will go through long cycles of testing and approval for their drugs. This means that investors sometimes have to postpone the use of lucrative future medication for months or even years.

1. Novo Nordisk A/S (NVO)

  • Revenue (TTM): $18.3 billion
  • Net Income (TTM): $5.8 billion
  • Market Cap: $118.6 billion
  • 1-Year Trailing Total Return: 0.5%
  • PE Ratio (TTM): 20.6

NOVO Nordisk is a global pharmaceutical corporation with offices in 80 countries and production facilities in seven continents. The primary subject of the company is diabetes, haemophilia, hormone production and hormone replacement. The company manufactures a range of medicines under different brands like Levemir, NovoLog, Novolin R, NovoSeven, NovoEight, and Victoza.

Novo Nordisk A/S (NVO) CEO Lars Fruergaard Jørgensen
Novo Nordisk A/S (NVO) CEO Lars Fruergaard Jørgensen

2. Regeneron Pharmaceuticals Inc. (REGN)

  • Revenue (TTM): $7.9 billion
  • Net Income (TTM): $2.1 billion
  • Market Cap: $49.5 billion
  • 1-Year Trailing Total Return: 14.7%
  • PE Ratio (TTM): 24.4

Regeneron (Nasdaq: REGN) is the leading biotechnology company that has developed life-producing drugs for people suffering from severe diseases. Our remarkable ability to turn science into medicine repeatedly and continuously was developed and led by doctors for over 30 years.

It resulted in seven therapies approved by the FDA and multiple drug applications under development, all of which were produced in our laboratories. Our medications and pipelines are targeted at supporting patients suffering from vision, allergic and inflammatory diseases, cancer, cardiovascular and metabolic disorders, infectious diseases, pain, rare diseases and other conditions.

The Regeneron business develop and markets prescription therapies for skin, lung, neurological, allergic and inflammatory disorders and infectious diseases patients. The company aims to conduct one of the largest gene sequencing operations in the world through its Regeneron Genetics Center.

Leonard S. Schleifer is the founder and chief executive of the <a class=biotechnology company Regeneron Pharmaceuticals” class=”wp-image-3752″/>
Leonard S. Schleifer is the founder and chief executive of the biotechnology company Regeneron Pharmaceuticals

3. Alexion Pharmaceuticals Inc. (ALXN)

  • Revenue (TTM): $5.0 billion
  • Net Income (TTM): $2.4 billion
  • Market Cap: $19.0 billion
  • 1-Year Trailing Total Return: -34.1%
  • PE Ratio (TTM): 8.0

Our knowledge of rare diseases continues, which has begun with our groundbreaking research in biological complements. This expertise enables us to evolve and expand into new areas where patients and families live their best lives fully.

We’ve delivered transformative medicines for people with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD), generalized Myasthenia Gravis (gMG), hypophosphatasia (HPP), and lysosomal acid lipase deficiency (LAL-D).

Ludwig Norbert Michel Hantson is a Belgium businessman, the CEO of Alexion Pharmaceuticals since March 2017. He was the president and CEO of Baxalta, an American biopharmaceutical company, from 2015 to 2016
Ludwig Norbert Michel Hantson is a Belgium businessman, the CEO of Alexion Pharmaceuticals since March 2017. He was the president and CEO of Baxalta, an American biopharmaceutical company, from 2015 to 2016

4. Vertex Pharmaceuticals Inc. (VRTX)

  • Revenue (TTM): $4.2 billion
  • Net Income (TTM): $1.2 billion
  • Market Cap: $57.9 billion
  • 1-Year Trailing Total Return: 22.9%
  • PE Ratio (TTM): 49.5

Vertex is a multinational pharmaceutical firm investing in medical research to develop innovative medicines for people with life threatening and serious diseases.

The first medicines to treat the underlying cause of cystic fibrosis (CF), a rare genetic disease threatening life, have been discovered and established. Vertex has more than a dozen research projects focused on the underlying mechanisms of other severe diseases in addition to clinical development programs in the field of CF.

Our corporate headquarters was founded in 1989 in Cambridge, Massachusetts, and is currently located within Boston’s Innovation District, London, UK. Currently we employ around 2 500 people, with almost two thirds of our research and development staff in the United States, Europe, Canada, Australia and Latin America.

Vertex has always been recognized by Science Magazine, The Boston Globe, Boston Business Journal, and San Diego Business Journal as one of the leading businesses in the industry. The Robert J. Ball Therapeutics Development Award, the French Prix Galien and the British Pharmacological Society have also been recognized in our research and medicine.

Reshma Kewalramani, is the president and chief executive officer of Vertex Pharmaceuticals, a biotechnology company based in Boston, Massachusetts, as of April 1, 2020. She is the first female CEO of a large US biotech company.
Reshma Kewalramani, is the president and chief executive officer of Vertex Pharmaceuticals, a biotechnology company based in Boston, Massachusetts, as of April 1, 2020. She is the first female CEO of a large US biotech company.

5. Jazz Pharmaceuticals PLC (JAZZ)

  • Revenue (TTM): $2.2 billion
  • Net Income (TTM): $0.5 billion
  • Market Cap: $5.4 billion
  • 1-Year Trailing Total Return: -30.0%
  • PE Ratio (TTM): 10.5

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company which develops medicines for the changing lives of individuals with or without limited options to enhance their full lives. By converting bio-pharmaceutical findings into new medicines, we strive to give people worldwide the opportunity of redefining what can be done – and to redefine “small winners.”

We develop meaningful medicines and bring them to people with unsatisfactory requirements around the world, as a leader in sleep medicine and with an increasing hematology / oncology range. We seek solutions for rare or complex diseases and ensure that the often-overlooked patients that need them are able to find these solutions.

Our R&D capabilities have also expanded as the field of science. We are exploring revolutionary medicines, ranging from small molecular progressions to biologics, to find new compounds in sleep medicine and oncology. This dynamic approach has made it possible for us to market new drugs from late finding via clinical development and regulatory approval. All these progresses reflect our continuing investment in a changing and growing focus on research and development.

Jazz Pharmaceuticals PLC (JAZZ)

6. Incyte Corp. (INCY)

  • Revenue (TTM): $2.2 billion
  • Net Income (TTM): $0.5 billion
  • Market Cap: $14.6 billion
  • 1-Year Trailing Total Return: -21.0%
  • PE Ratio (TTM): 32.9

Incyte is a worldwide biopharmaceutical company based on the premise that investment in science and in the constant pursuit of research and development excellence can lead to new solutions that have a positive influence on patient lives.

In 2002, a team of immunology researchers, chemists and biologists in Wilmington, Delaware, founded our drug discovery and development efforts. We currently employ over 1,400 people and operate in the United States, Europe and Japan. Top Biotech companies in the world.

Our unique medical chemical and biology expertise has made it possible to create a diversified portfolio, most of which were discovered by the scientists of Incyte, of commercialized products and clinical candidates. In the two franchises: oncology and inflammation & autoimmunity, we are advancing an increasing pipeline of medicines.

Our talented international team of scientists has enabled us to determine new molecules, unravel new pathways and develop top-quality and top-notch medicines.

HERVÉ HOPPENOT

Chairman, President and Chief Executive Officer
HERVÉ HOPPENOT
Chairman, President and Chief Executive Officer

Hervé Hoppenot joined Incyte in 2014 as President and Chief Executive Officer, and was appointed Chairman of the Board of Directors in 2015.

During Mr Hoppenot’s tenure, the Company has tripled the number of clinical candidates in its portfolio, expanding beyond oncology to include research and development in inflammation & autoimmunity. Under his leadership, revenue has increased by over 400 per cent, which includes the addition of two new revenue streams; and, with a goal to deliver medicines to patients worldwide, the Company has expanded geographically beyond the U.S. to include operations in 10 EU countries and Japan.

7. Biomarin Pharmaceutical Inc. (BMRN)

  • Revenue (TTM): $1.7 billion
  • Net Income (TTM): -$0.02 billion
  • Market Cap: $14.4 billion
  • 1-Year Trailing Total Return: -9.3%
  • PE Ratio (TTM): N/A

BioMarin is a world leader in developing and commercializing innovative biopharmaceuticals for rare diseases driven by genetic causes.

At BioMarin we concentrate on developing first-class therapeutics that provide significant progress for patients with rare genetic diseases that face serious and life threats. BioMarin continues to pursue its original mission — to bring on the market new treatments that will greatly influence small populations of patients. Most of these patient populations suffer from diseases so rarely, that there are as few as 1,000 people worldwide. These populations are children. Often these diseases are inherited, hard to diagnose, gradually weakening, have few or no treatment options, and are usually ignored.

Time is critical and we are working on developing important therapies for rare diseases patients quickly. Our ability to provide therapy urgently depends on the efficiency and the speed of our research, development, manufacturing and marketing efforts.

We are significantly faster than the industry average and are in our culture than we had before with the development and commercialisation of new treatments. CenterWatch has made it one of the fastest drug developers in the industry and one of the world’s leading providers of information on clinical trials. Also in the 2015 Forbs list of innovative companies, BioMarin was ranked tenth. Top Biotech companies in the world

As a biopharmaceutical company, the focus on science and the hope our treatments can bring to patients is our success. Our success. With a number of products marketed and an increasing number of product candidates, we are world leaders in the field of metabolic disease innovation to respond to unmet medical needs. We keep driving our R&D engine by seeking opportunities that align with our strengths and skills. We continue in the early stages of exciting science, which is capable of changing the course of the disease.

A maker of therapeutic enzyme products, Biomarin Pharmaceutical develops drug treatments for lysosomal storage diseases as well as serious burns. The company also provides diagnostic and analytic services for carbohydrate biology applications.

Jean-Jacques Bienaime
Chairman and Chief Executive Officer
Jean-Jacques Bienaime
Chairman and Chief Executive Officer

At present, Mr. Bienaimé is President and CEO of BioMarin. In May 2005, he joined the company, with over 25 years of biotechnology and pharmaceutical industry experience, as Chief Executive Officer and Member of the Board of Directors. The market capitalization of BioMarin, under his leadership, went from around $450 million to around $14 billion in the summer of 2019 in May 2005. Revenues of $1.5 billion from BioMarin 2018 over the full year. With over 2,800 employees worldwide, BioMarin is a fully integrated biopharmaceutical firm.

8. United Therapeutics Corp. (UTHR)

  • Revenue (TTM): $1.4 billion
  • Net Income (TTM): -$0.1 billion
  • Market Cap: $3.9 billion
  • 1-Year Trailing Total Return: -27.1%
  • PE Ratio (TTM): N/A

The focus of United Therapeutics Corporation is on the strength of a balanced biotechnology model that provides value. With our basic characteristics, namely our obsession with quality and innovation, the power of our brands, our business culture and our leadership in bioinformatics, we are confident in our future. We also believe our determination – with a positive impact on patients, the environment and society-to be a responsible citizen will sustain our long-term success.

United Therapeutics primarily develops drug treatments for pulmonary hypertension, peripheral vascular disease, and other vascular conditions. Among the company’s most popular medicines are Remodulin, Orenitram, Unituxin, and Tyvaso.

We are focusing on addressing the acute national lack of transplantable lung and other organs with various technology, through our wholly owned subsidiary Lung Biotechnology PBC, that either retards or increases the supply of such organs. Lung Biotechnology is a subsidiary of public biotechnology or pharmaceutical company that is the first public benefit company.

Martine Rothblatt
CEO of United Therapeutics Corporation
Martine Rothblatt
CEO of United Therapeutics Corporation

9. Alkermes PLC (ALKS)

  • Revenue (TTM): $1.2 billion
  • Net Income (TTM): $-0.2 billion
  • Market Cap: $2.2 billion
  • 1-Year Trailing Total Return: -58.6%
  • PE Ratio (TTM): N/A

Alkermes is a leader in innovative medicines that address the unsatisfactory needs and challenges of weaker people. Alkermes, a fully integrated global biopharmaceutical company, applies our scientific expertise, proprietary technologies and global resources to the development of products designed to make a significant difference to the management of patients.

Track Record of Innovation

Through our proven scientific, development and manufacturing capabilities, Alkermes is uniquely positioned to be an engine of innovative treatments for major clinical conditions specifically focused on neuroscience and oncology. Top Biotech companies in the world

The success of our approach is reflected in:

  • Proven expertise reflected in a diversified commercial product portfolio;
  • A pipeline of novel product candidates in development for schizophrenia, bipolar I, neurodegenerative disorders and cancer;
  • Proprietary science and technology that leads to the discovery of new, patentable medicines; and
  • Our commitment to developing new treatment options for major diseases with patient needs in mind.
Richard Pops serves as Chairman and Chief Executive Officer of Alkermes. He joined Alkermes as CEO in 1991. Under his leadership, Alkermes has grown from a privately held company with 25 employees to an international, publicly traded biopharmaceutical company with more than 2,000 employees.
Richard Pops serves as Chairman and Chief Executive Officer of Alkermes. He joined Alkermes as CEO in 1991. Under his leadership, Alkermes has grown from a privately held company with 25 employees to an international, publicly traded biopharmaceutical company with more than 2,000 employees.

10. Ionis Pharmaceuticals Inc. (IONS)

  • Revenue (TTM): $1.1 billion
  • Net Income (TTM): $0.3 billion
  • Market Cap: $6.2 billion
  • 1-Year Trailing Total Return: -43.2%
  • PE Ratio (TTM): 21.7

Ionis is THE leading innovator in RNA-targeted therapeutics and was purposely designed to:

  • Create a better, more efficient drug discovery platform
  • Establish a new innovation-centred business model, and
  • Maximize the value of every medicine we create and get it to the people who need it most as quickly and as efficiently as possible

Today we are a sustainably profitable, multi-product company that is delivering transformative breakthroughs for patients… again and again.

Brett P. Monia, Ph.D.
Chief Executive Officer

Dr Monia is the CEO and Ionis Pharmaceuticals’ founding member. He contributed with Ionis to medicine research and RNA action mechanisms in the treatment of human diseases, especially therapeutic strategies based on anti-sense. Dr Monia has extensive experience in a variety of therapeutic areas, including oncology, metabolic diseases, inflammation, neurological diseases and cardiovascular diseases, which has led to a wide range of successful clinical results and new medicinal products marketing approvals.

These were the Top Biotech companies in the world – 2020. Keep following us for the latest updates.

Bioinformatics India
Logo